Tumor Immunology meets…Immunology: Modified cancer cells as professional APC for priming naïve tumor-specific CD4+ T cells

• Main Authors: Farah Bou Nasser Eddine, Elise Ramia, Giovanna Tosi, Greta Forlani, Roberto S. Accolla
• Format: Article
• Language: English
• Published: Taylor & Francis Group 2017-11-01
• Series: OncoImmunology
• Subjects: mhc class ii transactivator; apc; t helper cells; anti-tumor vaccines
• Online Access: http://dx.doi.org/10.1080/2162402X.2017.1356149

Although recent therapeutic approaches have revitalized the enthusiasm of the immunological way to combat cancer, still the comprehension of immunity against tumors is largely incomplete. Due to their specific function, CD8+ T cells with cytolytic activity (CTL) have attracted the attention of most investigators because CTL are considered the main effectors against tumor cells. Nevertheless, CTL activity and persistence is largely dependent on the action of CD4+ T helper cells (TH). Thus establishment of tumor-specific TH cell response is key to the optimal response against cancer. Here we describe emerging new strategies to increase the TH cell recognition of tumor antigens. In particular, we review recent data indicating that tumor cells themselves can act as surrogate antigen presenting cells for triggering TH response and how these findings can help in constructing immunotherapeutic protocols for anti-cancer vaccine development.